Plex Pharmaceuticals is a scientifically-driven biotechnology company focused on improving the lives of patients diagnosed with complex, degenerative diseases. Specializing in the treatment of diseases caused by protein mis-folding, such as ALS, Parkinson's Disease, and cataracts, Plex Pharmaceuticals has developed a rich pipeline of drug discovery programs. Their dedicated scientific team utilizes innovative approaches like fragment-based screening and structure-based drug design to develop effective treatments.

In addition to their work on protein misfolding diseases, Plex also has a development program for Dengue, West Nile, and Zika antiviral drugs. Their efforts have garnered support from the NIH and the Michael J. Fox Foundation.

Led by Chairman and CEO Hoji Alimi, the management team has a wealth of experience in the healthcare industry, having raised over $170 million for various ventures. Joining forces with Collidion, Inc